Eczacıbaşı Health Services was established in January 2001 to provide the first and most extensive “health service at site” in Turkey in cooperation with its international partner, the Corridor Group. Eczacıbaşı Health Services is the first large and organized concern in Turkey in the field of Home Care. The Corridor International is a consulting company, which has been giving home care and hospice service since 1989. In 1998, TGC was announced by Inc. Magazine to be one of the 500 most rapidly growing companies in the United States. The Corridor International, LLC was founded in 1999 with the aim of establishing home care services in Europe and Asia in a consultative capacity.

Patients who do not want to leave their comfortable bed at home, executives who would like to monitor the course of their illness without leaving their office, employers who want to have the health of their personnel checked, new mothers and infants who need support after childbirth have always been happy to find out that they were supported by the qualified, experienced, and the genial health personnel of Eczacıbaşı Health Services at their most difficult moments.

Eczacıbaşı Health Services is the first firm that aims to enable home care services to be understood and used by all sectors of society and to offer care for patients in its entirety inclusive of all related stages and support services (radiography, EKG, ultrasonography, laboratory services, medical devices and equipment).

Eczacıbaşı Health Services Company continues to collaborate with insurance companies through the renewal of the contracts it has made with regard to home care and newborn care. In addition, it maintains its home physician, home nurse, home health support personnel and home therapist services.

In the institution, where all medical records are kept electronically with the help of special software, patients are monitored by physicians and specialized nurses.

In addition to home care services, Eczacıbaşı Health Services also maintains its activities in accordance with the “Disease Management Program” that began in 2005 in cooperation with insurance companies and pharmaceutical concerns related to chronic diseases such as hypertension, diabetes, and dislipidemy.